

Public Disclosures of Individual Financial Conflicts of Interest

The University of Utah Individual Conflict of Interest Committee has determined that the following conflicts of interest should be disclosed to the public. The Committee has established a management plan in cooperation with the individuals listed below to address the conflicts of interest.

[Conflict of Interest Policy \(1-006\)](#)

Investigator	Investigator's Title/Role	Title of Research Project	Business Entity	Nature of Financial Interest	Approximate Dollar Value
Agarwal, Jay	Associate Professor and Co-Investigator	TCIP Vessel Coupling	N/A	Intellectual Property	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
Agarwal, Jay	Associate Professor and Co-Investigator	Safety Study of Percutaneous Osseointegrated Iplants for Prosthetic Attachment	N/A	Intellectual Property	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
Agarwal, Jay	Associate Professor and Co-Investigator	Safety Study of Percutaneous Osseointegrated Iplants for Prosthetic Attachment	DJO Surgical	Consulting	\$10,000-19,999
Ambati, Bala	Professor and Principal Investigator	Intracaptor Interference of VEGF in Ocular Angiogenesis	N/A	Intellectual Property	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
Ambati, Bala	Professor and Principal Investigator	Intracaptor Interference of VEGF in Ocular Angiogenesis	iVeena	Equity Interest	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
Aston, Kenneth	Assistant Professor and Co-Investigator	Epigenetics of the Paternal Contribution to Pediatric Cancer Risk	N/A	Intellectual Property	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
Bamberg, Stacy	Associate Professor and Co-Investigator	Subcontract from Veristride, Inc. for Motion Analysis	Veristride, Inc.	Income	\$10,000-19,999
Bamberg, Stacy	Associate Professor and Co-Investigator	Subcontract from Veristride, Inc. for Motion Analysis	Veristride, Inc.	Equity Interest	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
Bernard, Phil	Associate Professor and Co-Investigator	GENETIC EPIDEMIOLOGY OF BREAST CANCER	Bioclassifier	Equity Interest	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
Bernstein, Paul	Professor and Principal Investigator	Macular Pigment Imaging in Infants using the RetCam	N/A	Intellectual Property	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
Blair, Steve	Professor and Co-Investigator	Thin film spectacle coatings to reduce light sensitivity and headaches in child and adolescent patients with migraine	N/A	Intellectual Property	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
Blair, Steve	Professor and Co-Investigator	Thin film spectacle coatings to reduce light sensitivity and headaches in patients with migraine.	N/A	Intellectual Property	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
Blaschke, Anne	Associate Professor and Co-Investigator	PARAPNEUMONIC EMPYEMA: USE OF MOLECULAR METHODS TO IDENTIFY PATHOGENS AND OUTCOME	N/A	Intellectual Property	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
Blaschke, Anne	Associate Professor and Principal Investigator	PCR-Based Identification of Pathogenic Organisms from Blood Culture and CSF	N/A	Intellectual Property	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

Blaschke, Anne	Associate Professor and Co-Investigator	Mortality and Morbidity Associated with Respiratory Viral Infection in Infants following Congenital Heart Disease Surgical Repair	N/A	Intellectual Property	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
Blaschke, Anne	Associate Professor and Co-Investigator	Molecular Classification of Pediatric Cancer	N/A	Intellectual Property	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
Blaschke, Anne	Associate Professor and Principal Investigator	PCR for the Diagnosis of Bloodstream Infection in the NICU	N/A	Intellectual Property	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
Blaschke, Anne	Associate Professor and Co-Investigator	Molecular Evaluation of Pediatric Joint Fluid	N/A	Intellectual Property	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
Blaschke, Anne	Associate Professor and Principal Investigator	Real-Time Multiplex PCR for Diagnosis of Bacterial and Viral Infections in Children	N/A	Intellectual Property	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
Blaschke, Anne	Associate Professor and Co-Investigator	Epidemiology and Etiology of Hospitalized Pneumonia in Children	N/A	Intellectual Property	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
Bloebaum, Roy	Research Professor and Principal Investigator	PREVENTION OF BIOFILM RELATED INFECTIONS USING A NOVEL, BROAD SPECTRUM ANTIMICROBIAL COATING, CSA-13, ON ORTHOPEDIC FIXATION PLATES	N/A	Intellectual Property	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
Bosque, Alberto	Research Assistant Professor and Principal Investigator	Reactivation of latent HIV through TLR signaling	N/A	Intellectual Property	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
Box, Terry	Associate Professor (Clinical) and Principal Investigator	GS-US-248-0123: A Long Term Follow-up Registry Study of Subjects Who Did Not Achieve Sustained Virologic Response in Gilead- Sponsored Trials in Subjects with Chronic Hepatitis C Infection	Gilead Pharmaceuticals	Speaking Honoraria	\$5,000-9,999
Box, Terry	Associate Professor (Clinical) and Principal Investigator	Increased Hepatitis C Screening and Linkage to Care for Patients in Utah with the Utilization of the Project ECHO Model	Genentech	Speaking Honoraria	\$10,000-19,999
Box, Terry	Associate Professor (Clinical) and Principal Investigator	Increased Hepatitis C Screening and Linkage to Care for Patients in Utah with the Utilization of the Project ECHO Model	Merck Pharmaceutical	Speaking Honoraria	\$10,000-19,999
Box, Terry	Associate Professor (Clinical) and Principal Investigator	Increased Hepatitis C Screening and Linkage to Care for Patients in Utah with the Utilization of the Project ECHO Model	Vertex Pharmaceutical	Speaking Honoraria	\$5,000-9,999
Brodke, Darrel	Professor and Principal Investigator	Early and Late Complications after surgical treatment of Adult Deformity	Amedica	Equity Interest	\$40,000-59,999
Brodke, Darrel	Professor and Principal Investigator	Early and Late Complications after surgical treatment of Adult Deformity	Pioneer Surgical Technology	Equity Interest	\$5,000-9,999
Brodke, Darrel	Professor and Principal Investigator	Early and Late Complications after surgical treatment of Adult Deformity	Vertiflex	Equity Interest	\$5,000-9,999
Burks, Robert	Professor and Principal Investigator	Acquisition and Maintenance of Skills in Arthroscopy Using High Fidelity Virtual Reality Simulation	VirtaMed	Consulting	\$5,000-9,999
Burt, Randy	Professor and Co-Investigator	Inheritance Of Colon Cancer: A Sibling Pair Study	Myriad Genetics	Consulting	\$5,000-9,999
Burt, Randy	Professor and Co-Investigator	High Risk Familial Colon Cancer: Genetics And Phenotype	Myriad Genetics	Consulting	\$5,000-9,999
Burt, Randy	Professor and Co-Investigator	Characterizing the molecular signatures of rare inherited colon cancer syndromes for diagnosis and intervention	Myriad Genetics	Consulting	\$5,000-9,999
Burt, Randy	Professor and Principal Investigator	MOLECULAR AND CLINICAL APPROACHES TO COLON CANCER PRECURSORS	Myriad Genetics	Consulting	\$5,000-9,999

Burt, Randy	Professor and Co-Investigator	Effects of Environment and Inheritance on Colonic Polyps	Myriad Genetics	Consulting	\$5,000-9,999
Burt, Randy	Professor and Co-Investigator	Genetic Characterization of Cancer Risk in Families, Phase 2	Myriad Genetics	Consulting	\$5,000-9,999
Byington, Carrie	Professor and Co-Investigator	Real-Time Multiplex PCR for Diagnosis of Bacterial and Viral Infections in Children	N/A	Intellectual Property	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
Byington, Carrie	Professor and Co-Investigator	Epidemiology and Etiology of Hospitalized Pneumonia in Children	N/A	Intellectual Property	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
Byington, Carrie	Professor and Co-Investigator	PCR for the Diagnosis of Bloodstream Infection in the NICU	N/A	Intellectual Property	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
Carrell, Douglas	Professor and Principal Investigator	Epigenetics of the Paternal Contribution to Pediatric Cancer Risk	Espiona	Equity Interest	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
Carrell, Douglas	Professor and Principal Investigator	Micro-Electrophoresis: A novel approach to select mature and genetically fit sperm	N/A	Intellectual Property	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
Carrell, Douglas	Professor and Co-Investigator	Epigenetic Changes Associated with High Dose Chemotherapy	N/A	Intellectual Property	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
Chan, Gary	Professor and Co-Investigator	Macular Pigment Imaging in Infants using the RetCam	Abbott Nutritional	Honoraria	\$10,000-19,999
Chan, Gary	Professor and Co-Investigator	PRETERM INFANTS AND NEPHROCALCINOSIS: DIAGNOSIS AND PATHOGENESIS	Abbott Nutritional	Honoraria	\$10,000-19,999
Chan, Gary	Professor and Co-Investigator	Comparison of Two Human Milk Fortifiers in Preterm Infants	Abbott Nutritional	Honoraria	\$10,000-19,999
Clegg, Daniel	Professor and Co-Investigator	A Double Blind, Placebo Controlled, Phase II, Randomized Study of Lovastatin Therapy in the Treatment of Mildly Active Rheumatoid Arthritis	Novartis	Consulting	\$5,000-9,999
Colman, Howard	Associate Professor and Co-Investigator	BTTC 12-01: A Phase II Trial of Oral Pazopanib Plus Oral Topotecan Metronomic Antiangiogenic Therapy for Recurrent Glioblastoma Multiforme (A) without Prior Bevacizumab Exposure and (B) after Failing Prior Bevacizumab	Hoffman La Roche/Genetech	Honoraria	\$5,000-9,999
Colman, Howard	Associate Professor and Co-Investigator	A Phase 1b/2 Study of Repeat rAdiation, Minocycline, and Bevacizumab in patients with recurrent glioma (RAMBO)	Hoffman La Roche/Genetech	Honoraria	\$5,000-9,999
Colman, Howard	Associate Professor and Co-Investigator	GSK EGF111767: An Open-Label, Phase Ib Continuation Study of Lapatinib Monotherapy or Lapatinib in Combination with other Anticancer Treatment in Patients with Solid Tumors	Hoffman La Roche/Genetech	Honoraria	\$5,000-9,999
Colman, Howard	Associate Professor and Principal Investigator	Alliance A071101 >> A Phase II Randomized Trial Comparing the Efficacy of Heat Shock Protein-Peptide Complex-96 (HSPPC-96) (NSC #725085, Alliance IND# 15380) Vaccine Given with Bevacizumab Versus Bevacizumab Alone in the Treatment of Surgically Resectabl	Hoffman La Roche/Genetech	Honoraria	\$5,000-9,999
Converse, Matthew	Graduate Assistant and Co-Investigator	Clinical value and cost-effectiveness of clinic-based uroflowmetry in the evaluation of urologic conditions.	Stream Dx	Equity Interest/Intellectual Property	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
Converse, Matthew	Graduate Assistant and Co-Investigator	Validation study of urine flow rate monitoring with novel device: StreamDx.	Stream Dx	Equity Interest/Intellectual Property	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
Deinger, Michael	Professor and Principal Investigator	OHSU IIT Incyte 10262>>Prospective Evaluation of Ruxolitinib Efficacy for CNL/aCML Patients with Mutation of CS3FR	Incyte	Consulting	\$5,000-9,999

Deining, Michael	Professor and Co-Investigator	BMS CA209-139>>A Single-Arm, Open-Label Phase 2 Study of Nivolumab (BMS-936558) in Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) After Failure of Autologous Stem Cell Transplant (ASCT) or After Failure of At Least One Prior M	Bristol-Myers Squibb	Consulting	\$5,000-9,999
Deining, Michael	Professor and Co-Investigator	Resource Utilization for the Management of Chronic Myeloid Leukemia in a Comprehensive Cancer Center Network Database	Novartis	Consulting	\$10,000-19,999
Deining, Michael	Professor and Principal Investigator	Pfizer B1371013>>A Phase 2, Double-Blind, Randomized Safety And Efficacy Study Of PF-04449913 Versus Placebo With Defined Best Supportive Therapy Allowed In Both Arms In Patients With Myelofibrosis Previously Treated With One Or More Janus Kinase Inhibit	Pfizer	Consulting	\$5,000-9,999
Deining, Michael	Professor and Principal Investigator	Outcomes and prognostic factors in chronic myelomonocytic leukemia (CMML)	Novartis	Consulting	\$10,000-19,999
Di Bella, Edward	Professor and Co-Investigator	Multi-Tracer PET Tumor Imaging	N/A	Intellectual Property	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
Downey, Earl	Professor (Clinical) and Co-Investigator	Upper Extremity Biomechanics and Ergonomic Assessment of Laparoscopic Surgery Instruments with an Inanimate Box Trainer	N/A	Intellectual Property	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
Dudek, Ed	Professor and Principal Investigator	TARGETED INTERNEURON ABLATION AND EPILEPTOGENESIS	Epitel	Equity Interest/Intellectual Property	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
Dudek, Ed	Professor and Principal Investigator	IVERMECTIN ACTIVATED HUMAN GLYCINE RECEPTOR SUPPRESSION OF PHARMACORESISTENT EPILEPSY	Epitel	Equity Interest/Intellectual Property	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
Eckert, Debra		D-PEPTIDE INHIBITORS OF HIV-1 ENTRY	Navigen	Equity Interest/Intellectual Property	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
Esplin, Sean	Professor and Co-Investigator	Genomics and Proteomics Network for Preterm Birth Research: Longitudinal Study	Sera Prognostics	Equity Interest/Intellectual Property	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
Esplin, Sean	Professor and Co-Investigator	Genomics and Proteomics Network for Preterm Birth: Expression Profiling Study	Sera Prognostics	Equity Interest/Intellectual Property	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
Esplin, Sean	Professor and Co-Investigator	Genomic and Proteomic Network for Preterm Birth Research: Case Control Study	Sera Prognostics	Equity Interest/Intellectual Property	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
Fang, John	(Clinical) Professor and Principal Investigator	Placement of Veritract Smart Feeding Tube: Healthy Human Volunteer Study	Veritract	Equity Interest/Intellectual Property	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
Fassi, Bernhard	Assistant Professor (Clinical) and Co-Investigator	Organizational Factors Associated with Improved Inpatient Pediatric Asthma Care	N/A	Intellectual Property	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
Firpo, Matthew	Research Associate Professor and Co-Investigator	A Feasibility Study for the Early Detection of Pancreatic Cancer	N/A	Intellectual Property	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

Freedman, Roger	Professor (Clinical) and Principal Investigator	AdaptResponse	Medtronic	Consulting	\$5,000-9,999
Fu, Yingbin	Associate Professor and Co-Investigator	Mechanisms and treatment strategies for polypoidal choroidal vasculopathy	N/A	Intellectual Property	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
Hotaling, James	Assistant Professor and Co-Investigator	Validation study of urine flow rate monitoring with novel device: StreamDx.	N/A	Intellectual Property	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
Hotaling, James	Assistant Professor and Co-Investigator	Clinical value and cost-effectiveness of clinic-based uroflowmetry in the evaluation of urologic conditions.	N/A	Intellectual Property	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
Hotaling, James	Assistant Professor and Co-Investigator	Preliminary investigation of erectile function using a non-invasive measurement device	Andro360	Equity Interest	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
Jenkins, Tim	Research Associate and Co-Investigator	Epigenetics of the Paternal Contribution to Pediatric Cancer Risk	N/A	Intellectual Property	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
Jones, Greg	Assistant VP for Research and Co-Investigator	Automated Problem and Allergy Lists Enrichment Based on High Accuracy Information Extraction from the Electronic Health Record	Clinacuity	Equity Interest	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
Jones, Greg	Assistant VP for Research and Co-Investigator	Automated Dynamic Lists for Efficient Electronic Health Record Management	Clinacuity	Equity Interest	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
Kadmas, Dan	Professor and Principal Investigator	Multi-Tracer PET/CT Imaging of Gemcitabine Response in Pancreatic Cancer	MultiFunctional Imaging, LLC	Equity Interest/Intellectual Property	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
Kadmas, Dan	Professor and Principal Investigator	Multi-Tracer PET Tumor Imaging	MultiFunctional Imaging, LLC	Equity Interest/Intellectual Property	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
Katz, Bradley	Associate Professor and Co-Investigator	Thin film spectacle coatings to reduce light sensitivity and headaches	N/A	Intellectual Property	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
Kay, Michael	Professor and Principal Investigator	D-PEPTIDE INHIBITORS OF HIV-1 ENTRY	Navigen	Equity Interest/Intellectual Property	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
Kholmovski, Evgueni	Research Assistant Professor and Principal Investigator	Cardiac MRI Techniques for Atrial Fibrillation Research and Management	N/A	Intellectual Property	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
Kim, Sung Wan	Professor and Principal Investigator	Design of Oncolytic Adenovirus Conjugated with Novel Polymer for Cancer Treatment	N/A	Intellectual Property	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
Kovacs, Tibor	Professor (Clinical) and Principal Investigator	Celgene CC-4047-MM-007>>A Phase 3, Multicenter, Randomized, Open-label Study to Compare the Efficacy and Safety of Pomalidomide (POM), Bortezomib (BTZ) and Low-Dose Dexamethasone (LD-DEX) versus Bortezomib and Low-Dose Dexamethasone in Subjects with Relapsed Multiple Myeloma	Celgene	Honoraria	\$10,000-19,999

Kovacovics, Tibor	Professor (Clinical) and Principal Investigator	Celgene CC-4047-MM-007>>A Phase 3, Multicenter, Randomized, Open-label Study to Compare the Efficacy and Safety of Pomalidomide (POM), Bortezomib (BTZ) and Low-Dose Dexamethasone (LD-DEX) versus Bortezomib and Low-Dose Dexamethasone in Subjects with Relapsed Multiple Myeloma	Celgene	Equity Interest	\$10,000-19,999
Krizaj, David	Professor and Principal Investigator	The role of mechanosensation in the vertebrate retina	AshaVision	Equity Interest/Intellectual Property	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
Krueger, Gerald	Professor and Co-Investigator	A Phase 3 Study to Evaluate the Efficacy Safety, and Effect of Withdrawal and Retreatment with Brodalumab in Subjects with Moderate to Severe Plaque Psoriasis : AMAGINE-1	Amgen/Immunex	Income for Consulting/Education/Speaking	\$10,000-19,999
Krueger, Gerald	Professor and Co-Investigator	Abbott Fellowship 2014	Abbott Pharmaceutical	Income for Consulting/Education/Speaking	\$20,000-39,999
Krueger, Gerald	Professor and Co-Investigator	A Multicenter, Open Registry of Patients with Psoriasis Who Are Candidates for Systemic Therapy Including Biologics	Janssen Pharmaceutical Inc	Income for Consulting/Education/Speaking	\$20,000-39,999
Krueger, Gerald	Professor and Co-Investigator	CNTO1959PSO3002- A Phase 3, Multicenter, Randomized, Double-blind, Placebo and Active Comparator-controlled Study Evaluating the Efficacy and Safety of Guselkumab in the Treatment to Subjects with Moderate to Severe Plaque-type Psoriasis with Randomized	Janssen Pharmaceutical Inc	Income for Consulting/Education/Speaking	\$20,000-39,999
Krueger, Gerald	Professor and Co-Investigator	Efficacy of Ustekinumab (Anti-IL-12/23) followed by Abatacept (CTLA4-Ig) for the Treatment of Psoriasis Vulgaris Protocol ITN059AI (Pause Study) Version 2.0 30SEP2013	Abbott Pharmaceutical	Income for Consulting/Education/Speaking	\$20,000-39,999
Krueger, Gerald	Professor and Co-Investigator	A Phase 3 Study to Evaluate the Efficacy and Safety of Induction and Maintenance Regimens of Brodalumab Compared With Placebo and Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis: AMAGINE-3	Amgen/Immunex	Income for Consulting/Education/Speaking	\$20,000-39,999
Krueger, Gerald	Professor and Co-Investigator	Clinical Trial Protocol CAIN457AUS01 A randomized, double-blind, placebo-controlled, parallelgroup, multicenter study to demonstrate the efficacy of subcutaneous secukinumab [300 mg] as assessed by the Psoriasis Scalp Severity Index (PSSI) at 12 weeks of treatment, compared to placebo, and to assess safety and tolerability up to 24 weeks in adult subjects with moderate to severe scalp psoriasis.	Novartis	Income for Consulting/Education/Speaking	\$10,000-19,999
Krueger, Gerald	Professor and Co-Investigator	CNTO1959PSO3001 - A Phase 3, Multicenter, Randomized, Double-blind, Placebo and Active Comparator-controlled Study Evaluating the Efficacy and Safety of Guselkumab for the Treatment of Subjects with Moderate to Severe Plaque-type Psoriasis	Janssen Pharmaceutical Inc	Income for Consulting/Education/Speaking	\$20,000-39,999
Krueger, Gerald	Professor and Co-Investigator	A Phase 3 Study to Evaluate the Efficacy Safety, and Effect of Withdrawal and Retreatment with Brodalumab in Subjects with Moderate to Severe Plaque Psoriasis : AMAGINE-1	Amgen/Immunex	Income for Consulting/Education/Speaking	\$20,000-39,999
Krueger, Gerald	Professor and Co-Investigator	Vascular Inflammation in Psoriasis Extension (VIP-E) Trial	Abbott Pharmaceutical	Income for Consulting/Education/Speaking	\$20,000-39,999
Krueger, Gerald	Professor and Co-Investigator	Vascular Inflammation in Psoriasis Trial (VIP) Protocol #814278 (A Trial to Determine the Effect of Psoriasis Treatment on Cardiometabolic Disease)	Abbott Pharmaceutical	Income for Consulting/Education/Speaking	\$20,000-39,999
Kubiak, Erik	Associate Professor and Principal Investigator	Safety Study of Percutaneous Osseointegrated Implants for Prosthetic Attachment	DJO Global	Consulting	\$10,000-19,999
Kubiak, Erik	Associate Professor and Co-Investigator	Retrieval and Analysis of Orthopedic Implants at Revision Arthroplasty Surgery	DJO Global	Consulting	\$10,000-19,999
LaStayo, Paul	Professor and Co-Investigator	Nutrient Regulation of Amino Acid Transporters in Aging Human Skeletal Muscle	N/A	Intellectual Property	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
LaStayo, Paul	Professor and Co-Investigator	The effect of a novel nutritional and contractile countermeasure on the regulation of protein synthesis in older adults with hip fracture	N/A	Intellectual Property	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

LaStayo, Paul	Professor and Principal Investigator	Reducing Falls with RENEW in Older Adults Who Have Fallen	N/A	Intellectual Property	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
LaStayo, Paul	Professor and Principal Investigator	Muscle atrophy regulation in older adults with hip fracture and potential anabolic approaches	N/A	Intellectual Property	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
Leachman, Sancy	Adjunct Professor and Co-Investigator	Cancer Genetics Study	Myriad Genetics	Consulting	\$5,000-9,999
Leachman, Sancy	Adjunct Professor and Co-Investigator	Molecular Classifications of Cancer	Myriad Genetics	Consulting	\$5,000-9,999
Lessnick, Stephen	Professor and Principal Investigator	Development of Specific and reversible LSD1 inhibitors for Ewing's Sarcoma.	Salaris Pharmaceuticals	Equity Interest	\$10,000-19,999
		(PQB-2) "Driver" vs. "passenger" epigenetic events in Ewing sarcoma	Salaris Pharmaceuticals	Equity Interest	\$10,000-19,999
Li, Dean	Professor and Principal Investigator	THE DEVELOPMENT OF SCREENING ASSAYS FOR NOVEL INHIBITOR OR ARNO AND ITS EFFECTOR, ARF6.	Navigen	Income for Consulting	\$60,000-79,999
Li, Dean	Professor and Principal Investigator	THE DEVELOPMENT OF SCREENING ASSAYS FOR NOVEL INHIBITOR OR ARNO AND ITS EFFECTOR, ARF6.	Navigen	Equity Interest	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
Li, Dean	Professor and Principal Investigator	High Content Screening for Hereditary Stoke Syndrome	Navigen	Income for Consulting	\$60,000-79,999
Li, Dean	Professor and Principal Investigator	High Content Screening for Hereditary Stoke Syndrome	Navigen	Equity Interest	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
Li, Dean	Professor and Principal Investigator	Interactions Of Endothelial Cells With Inflammatory Mediators.	Navigen	Income for Consulting	\$60,000-79,999
Li, Dean	Professor and Principal Investigator	Interactions Of Endothelial Cells With Inflammatory Mediators.	Navigen	Equity Interest	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
Li, Dean	Professor and Principal Investigator	Targeting cytokine-mediated pathologies for neuroprotection in	Navigen	Income for Consulting	\$60,000-79,999
Li, Dean	Professor and Principal Investigator	Targeting cytokine-mediated pathologies for neuroprotection in treatment of AMD	Navigen	Equity Interest	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
Li, Dean	Professor and Principal Investigator	Serum Biomarkers of Disease Severity in Hereditary Vascular Malformation Syndromes	Navigen	Income for Consulting	\$60,000-79,999
Li, Dean	Professor and Principal Investigator	Serum Biomarkers of Disease Severity in Hereditary Vascular Malformation Syndromes	Navigen	Equity Interest	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
Liu, Gang	Associate Professor and Co-Investigator	NOVEL THERAPEUTICS FOR POSTMENOPAUSAL OSTEOPOROSIS	Nanomedic, Inc.	Equity Interest	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
Livnat, Yarden	Adjunct Assistant Professor and Principal Investigator	An Automated System to Identify and Curate Web-based resources for Entrepreneurs	University Innovation Services,	Equity Interest/Intellectual Property	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
Livnat, Yarden	Adjunct Assistant Professor and Principal Investigator	Proposal to Create IPEnclave, a Machine Intelligence-based system for Innovative Organizations to Assess, Manage and License Intellectual Property	N/A	Intellectual Property	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
Livnat, Yarden	Adjunct Assistant Professor and Principal Investigator	Epinome TCIP	University Innovation Services,	Equity Interest/Intellectual Property	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

Livnat, Yarden	Adjunct Assistant Professor and Co-Investigator	Visual analytics and decision support for core public health missions	University Innovation Services,	Equity Interest/Intellectual Property	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
Livnat, Yarden	Adjunct Assistant Professor and Co-Investigator	Visual analytics and decision support for core public health missions	N/A	Intellectual Property	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
Maloney, Christopher	Professor (Clinical) and Co-Investigator	Organizational Factors Associated with Improved Inpatient Pediatric Asthma Care	N/A	Intellectual Property	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
Martin, James	Associate Professor and Principal Investigator	Active Desk: A Novel Invention for Improving Health in the Workplace	Active Desk	Equity Interest/Intellectual Property	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
Meystre, Stephane	Assistant Professor and Principal Investigator	Automated Problem and Allergy Lists Enrichment Based on High Accuracy Information Extraction from the Electronic Health Record	Clinacuity	CEO/Intellectual Property	\$0
Meystre, Stephane	Assistant Professor and Principal Investigator	Automated Dynamic Lists for Efficient Electronic Health Record Management	Clinacuity	CEO/Intellectual Property	\$0
Misra, Manoranjan	Professor and Principal Investigator	Rapid Diagnosis of Tuberculosis at the Point of Care Using a Handheld Volatile Biomarker Sensor	NANOSYNTH MATERIALS AND	Equity Interest/Intellectual Property	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
Morris, Alan	Professor and Co-Investigator	Cardiac Image Analysis for Atrial Fibrillation	N/A	Intellectual Property	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
Morton, David	Associate Professor (Lecturer) and Co-Investigator	Benefit Assessment of Premedical Anatomical Study for Medical Students	Amirsys	Consulting	\$10,000-19,999
Mulvihill, Sean	Associate Vice President and Principal Investigator	A Feasibility Study for the Early Detection of Pancreatic Cancer	N/A	Intellectual Property	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
Negi, Sandeep	Research Assistant Professor and Principal Investigator	Development and Commercialization of Next Generation of Neural Microelectrode Array	Blackrock Microsystems	Intellectual Property	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
Nirula, Raminder	Associate Professor and Principal Investigator	Patient Driven Surgical Discharge Process Improvement	N/A	Intellectual Property	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
Nirula, Raminder	Associate Professor and Principal Investigator	Patient evaluation and validation of a surgical discharge mobile application	ProMD	Equity Interest/Intellectual Property	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
Nkoy, Flory	Research Assistant Professor and Principal Investigator	Organizational Factors Associated with Improved Inpatient Pediatric Asthma Care	N/A	Intellectual Property	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
Oottamasathien, Siam	Associate Professor and Principal Investigator	Mechanisms for Bladder Inflammation and Fibrosis	Glycomira Therapeutics	Equity Interest/Intellectual Property	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
Orr, Joseph	Research Associate Professor and Co-Investigator	Investigation of a Novel Turbine-driven Ventilator for use in Cardiopulmonary Resuscitation	Anecare	Equity Interest/Intellectual Property	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

Ostafin, Agnes	Research Associate Professor and Principal Investigator	RETRIEVABLE BLOOD OXYGEN CARRIER SYSTEM BRIDGE FUNDS	Nanoshell Company, LLC	Equity Interest	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
Ostainin, Kirill	Adjunt Assistant Professor and Co-Investigator	THE DEVELOPMENT OF SCREENING ASSAYS FOR NOVEL INHIBITOR OR ARNO AND ITS EFFECTOR, ARF6.	Navigen	Salary	\$60,000-79,999
Pelt, Christopher	Assistant Professor and Principal Investigator	Retrieval and Analysis of Orthopedic Implants at Revision Arthroplasty Surgery	Biomet	Income for Consulting/Education/Speaking	\$10,000-19,999
Pelt, Christopher	Assistant Professor and Co-Investigator	AN MRI INVESTIGATION OF SOFT TISSUES FOLLOWING TOTAL HIP ARTHROPLASTY	Biomet	Income for Consulting/Education/Speaking	\$10,000-19,999
Pelt, Christopher	Assistant Professor and Co-Investigator	Randomized Controlled Clinical Outcomes of the Vanguard XP Bicruciate Knee System: GK9b	Biomet	Income for Consulting/Education/Speaking	\$10,000-19,999
Pelt, Christopher	Assistant Professor and Co-Investigator	A Clinical Evaluation of the Vanguard XP Bicruciate Knee System	Biomet	Income for Consulting/Education/Speaking	\$10,000-19,999
Pelt, Christopher	Assistant Professor and Co-Investigator	Clinical and Biomechanical Outcomes Following Total Knee Arthroplasty	Biomet	Income for Consulting/Education/Speaking	\$10,000-19,999
Pelt, Christopher	Assistant Professor and Co-Investigator	Vanguard SSK 360 Revision Knee System Global Data Collection	Biomet	Income for Consulting/Education/Speaking	\$10,000-19,999
Pelt, Christopher	Assistant Professor and Co-Investigator	Serum Metal Ion Concentrations Following Unilateral Versus Bilateral large Head Metal on Metal Primary Total Hip Arthroplasty	Biomet	Income for Consulting/Education/Speaking	\$10,000-19,999
Pelt, Christopher	Assistant Professor and Co-Investigator	Vanguard SSK 360 Revision Knee System Global Data Collection	Biomet	Income for Consulting/Education/Speaking	\$10,000-19,999
Pelt, Christopher	Assistant Professor and Co-Investigator	Retrieval and Analysis of Orthopedic Implants at Revision Arthroplasty Surgery	Biomet	Income for Consulting/Education/Speaking	\$10,000-19,999
Pelt, Christopher	Assistant Professor and Co-Investigator	Randomized Controlled Clinical Outcomes of the Vanguard XP Bicruciate Knee System: GK9b	Biomet	Income for Consulting/Education/Speaking	\$10,000-19,999
Pelt, Christopher	Assistant Professor and Co-Investigator	A Clinical Evaluation of the Vangaurd XP Bicruciate Knee System	Biomet	Income for Consulting/Education/Speaking	\$10,000-19,999
Peters, Christopher	Professor and Co-Investigator	AN MRI INVESTIGATION OF SOFT TISSUES FOLLOWING TOTAL HIP ARTHROPLASTY	Biomet	Income for Educational Courses	\$20,000-39,999
Peters, Christopher	Professor and Co-Investigator	AN MRI INVESTIGATION OF SOFT TISSUES FOLLOWING TOTAL HIP ARTHROPLASTY	Biomet	Royalty Income	\$900,000-999,999
Peters, Christopher	Professor and Co-Investigator	Vanguard SSK 360 Revision Knee System Global Data Collection	Biomet	Income for Educational Courses	\$20,000-39,999
Peters, Christopher	Professor and Co-Investigator	Vanguard SSK 360 Revision Knee System Global Data Collection	Biomet	Royalty Income	\$900,000-999,999
Peters, Christopher	Professor and Co-Investigator	Retrieval and Analysis of Orthopedic Implants at Revision Arthroplasty Surgery	Biomet	Income for Educational Courses	\$20,000-39,999
Peters, Christopher	Professor and Co-Investigator	Retrieval and Analysis of Orthopedic Implants at Revision Arthroplasty Surgery	Biomet	Royalty Income	\$900,000-999,999
Peters, Christopher	Professor and Co-Investigator	Clinical and Biomechanical Outcomes Following Total Knee Arthroplasty	Biomet	Income for Educational Courses	\$20,000-39,999
Peters, Christopher	Professor and Co-Investigator	Clinical and Biomechanical Outcomes Following Total Knee Arthroplasty	Biomet	Royalty Income	\$900,000-999,999
Peters, Christopher	Professor and Co-Investigator	Randomized Controlled Clinical Outcomes of the Vanguard XP Bicruciate Knee System: GK9b	Biomet	Income for Educational Courses	\$20,000-39,999
Peters, Christopher	Professor and Co-Investigator	Randomized Controlled Clinical Outcomes of the Vanguard XP Bicruciate Knee System: GK9b	Biomet	Royalty Income	\$900,000-999,999
Peters, Christopher	Professor and Co-Investigator	A Clinical Evaluation of the Vangaurd XP Bicruciate Knee System	Biomet	Income for Educational Courses	\$20,000-39,999
Peters, Christopher	Professor and Co-Investigator	A Clinical Evaluation of the Vangaurd XP Bicruciate Knee System	Biomet	Royalty Income	\$900,000-999,999
Peters, Christopher	Professor and Co-Investigator	AN MRI INVESTIGATION OF SOFT TISSUES FOLLOWING TOTAL HIP ARTHROPLASTY	Biomet	Income for Educational Courses	\$20,000-39,999
Peters, Christopher	Professor and Co-Investigator	AN MRI INVESTIGATION OF SOFT TISSUES FOLLOWING TOTAL HIP ARTHROPLASTY	Biomet	Royalty Income	\$900,000-999,999

Peterson, Kathryn	Associate Professor (Clinical) and Co-Investigator	Radioimaging Eosinophilia	Immviz	Equity Interest/Intellectual Property	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
Planelles, Vicente	Professor and Co-Investigator	Analysis of Latent HIV-1 Infection in Peripheral Blood Lymphocytes of Aviremic HIV-1 Infected Patients	N/A	Intellectual Property	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
Prestwich, Glenn	Professor and Co-Investigator	Treatment of Bladder Pain by Novel Glycosaminoglycan Derivatives	Glycomira Therapeutics	Equity Interest/Intellectual Property	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
Prestwich, Glenn	Professor and Principal Investigator	Anti-Inflammatory Glycosaminoglycan Ethers for Treatment of Periodontitis	Glycomira Therapeutics	Equity Interest/Intellectual Property	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
Sakata, Derek	Associate Professor (Clinical) and Co-Investigator	Investigation of a Novel Turbine-driven Ventilator for use in Cardiopulmonary Resuscitation	Anecare	Equity Interest	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
Sharma, Sunil	Professor and Principal Investigator	Protein targets of Gli, a protein originally isolated in human glioblastoma and an effector of Hedgehog (Hh) signaling (GLI) related targets	Beta Cat Pharmaceuticals	Equity Interest	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
Sharma, Sunil	Professor and Principal Investigator	LSD2 Inhibitors	Beta Cat Pharmaceuticals	Equity Interest	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
Sharma, Sunil	Professor and Co-Investigator	(PQB-2) "Driver" vs. "passenger" epigenetic events in Ewing sarcome	Beta Cat Pharmaceuticals	Equity Interest/Intellectual Property	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
Sharma, Sunil	Professor and Principal Investigator	Protein targets of Histone-lysine N-methyltransferase Enhancer of zeste homolog 2 (EZH2) related targets	Beta Cat Pharmaceuticals	Equity Interest	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
Shihab, Fuad	Professor (Clinical) and Principal Investigator	Retrospective Database Study Assessing the Impact of Tacrolimus Formulation Switching on Healthcare Resource Utilization, Trough Variability, and Clinical Outcomes Observational, Non-Interventional, Phase 4 Study (Protocol F506-MA-1000)	Astellas	Honoraria	\$5,000-9,999
Shihab, Fuad	Professor (Clinical) and Principal Investigator	A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial to Evaluate the Efficacy and Safety of a Vaccine, ASP0113, in Cytomegalovirus (CMV)-Seronegative Kidney Transplant Recipients Receiving an Organ from a CMV-Seropositive Donor	Astellas	Honoraria	\$5,000-9,999
Shihab, Fuad	Professor (Clinical) and Principal Investigator	Protocol 7163-CL-0108: A Phase 2a, Randomized, Open-Label, Active Control, Multi-Center Study to Assess the Efficacy and Safety of ASKP1240 in de novo Kidney Transplant Recipients	Astellas	Honoraria	\$5,000-9,999
Shihab, Fuad	Professor (Clinical) and Principal Investigator	(TRANSFORM) A 24 month, multicenter, randomized, open-label safety and efficacy study of concentration-controlled everolimus with reduced calcineurin inhibitor vs mycophenolate with standard calcineurin inhibitor in de novo renal transplantation-Advanci	Novartis	Consulting	\$10,000-19,999
Shprecher, David	Assistant Professor and Principal Investigator	PRIDE-HD: A Phase 2, Dose-Finding, Randomized, Parallel-Group, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Pridopidine 45 mg, 67.5 mg, 90 mg, and 112.5 mg Twice-Daily versus Placebo for Symptomatic Treatment in Patients w	Teva Neuroscience	Income for Speaking and Consulting	\$20,000-39,999

Shprecher, David	Assistant Professor and Principal Investigator	A 24-Week, Multicenter, Randomized, Double-blind, Placebo-Controlled, Add-on, Parallel-Group Study to Assess the Effect of Rasagiline on Cognition in Patients with Parkinson's Disease (TEVA - Moderato)	Teva Neuroscience	Income for Speaking and Consulting	\$20,000-39,999
Simon, Luke	Post Doctoral Fellow and Co-Investigator	A comparative analysis of sperm preparation methods to isolate genetically fit sperm	N/A	Intellectual Property	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
Simon, Luke	Post Doctoral Fellow and Co-Investigator	Micro-Electrophoresis: A novel approach to select mature and genetically fit sperm	N/A	Intellectual Property	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
Smith, John	Professor (Clinical) and Principal Investigator	Current Trends in the Treatment of Congenital Kyphosis	Depuy Synthes Spine	Income for Speaking and Education	\$5,000-9,999
Smith, John	Professor (Clinical) and Principal Investigator	Current Trends in the Treatment of Congenital Kyphosis	Depuy Synthes Spine	Intellectual Property	\$40,000-49,000
Southwick, Andrew	Associate Professor and Co-Investigator	Clinical value and cost-effectiveness of clinic-based uroflowmetry in the evaluation of urologic conditions.	Stream Dx	Intellectual Property	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
Southwick, Andrew	Associate Professor and Co-Investigator	Validation study of urine flow rate monitoring with novel device: StreamDx.	Stream Dx	Equity Interest/Intellectual Property	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
Stevens, Peter	Professor and Principal Investigator	Limb Deformity Registry	N/A	Intellectual Property	>\$100,000
Stevens, Peter	Professor and Principal Investigator	Ankle Valgus in Clubfeet: Outcomes Based on Treatment Method	Orthofix	Consulting/Intellectual Property	>\$100,000
Stone, Bryan	Associate Professor (Clinical) and Co-Investigator	Organizational Factors Associated with Improved Inpatient Pediatric Asthma Care	N/A	Intellectual Property	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
Taussky, Philipp	Adjunct Assistant Professor and Principal Investigator	Prospective Study on Embolization of Intracranial Aneurysms with Pipeline Embolization Device (PREMIER)	Covidien	Consulting	\$50,000-59,000
Thummel, Carl	Professor and Principal Investigator	Regulation of Metabolism in Drosophila	N/A	Intellectual Property	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
Turok, David	Associate Professor (Clinical) and Principal Investigator	The Copper T380A IUD vs. Oral Levonorgestrel for Emergency Contraception	Teva Women's Health	Salary for Advisory Board	\$5,000-9,999
Turok, David	Associate Professor (Clinical) and Principal Investigator	Intrauterine device insertion forces: successful insertions and perforations with LNG-20, T-380A, and Bioceptive inserters	Teva Women's Health	Salary for Advisory Board	\$5,000-9,999
Turok, David	Associate Professor (Clinical) and Principal Investigator	Patient discomfort with a novel suction based cervical retractor compared to the traditional cervical tenaculum	Teva Women's Health	Salary for Advisory Board	\$5,000-9,999
Tuteja, Ashok	Associate Professor (Clinical) and Principal Investigator	Diarrhea-Predominant Irritable Bowel Syndrome in First Gulf War Veterans-Revised	Salix Pharmaceutical	Consulting	\$5,000-9,999
Tuteja, Ashok	Associate Professor (Clinical) and Principal Investigator	Bacterial Overgrowth Associated with Chronic Multisymptom Illness Complex	Salix Pharmaceutical	Consulting	\$5,000-9,999
Weidner, Melissa	Research Nurse	Vascular Inflammation in Psoriasis Trial (VIP) Protocol #814278	Abbott Pharmaceutical	Spouse's Income for Consulting/Education/Speaking	\$20,000-39,999
Weidner, Melissa	Research Nurse and Co-Investigator	CNTO1959PSO3002- A Phase 3, Multicenter, Randomized, Double-blind, Placebo and Active Comparator-controlled Study Evaluating the Efficacy and Safety of Guselkumab in the Treatment to Subjects with Moderate to Severe Plaque-type Psoriasis with Randomized	Janssen Pharmaceutical Inc	Spouse's Income for Consulting/Education/Speaking	\$20,000-39,999
Weidner, Melissa	Research Nurse and Co-Investigator	CNTO1959PSO3001 - A Phase 3, Multicenter, Randomized, Double-blind, Placebo and Active Comparator-controlled Study Evaluating the Efficacy and Safety of Guselkumab for the Treatment of Subjects with Moderate to Severe Plaque-type Psoriasis	Janssen Pharmaceutical Inc	Spouse's Income for Consulting/Education/Speaking	\$20,000-39,999
Weidner, Melissa	Research Nurse and Co-Investigator	Efficacy of Ustekinumab (Anti-IL-12/23) followed by Abatacept (CTLA4-Ig) for the Treatment of Psoriasis Vulgaris Protocol ITN059AI (Pause Study) Version 2.0 30SEP2013	Abbott Pharmaceutical	Spouse's Income for Consulting/Education/Speaking	\$20,000-39,999

Weidner, Melissa	Research Nurse and Co-Investigator	A Phase 3 Study to Evaluate the Efficacy and Safety of Induction and Maintenance Regimens of Brodalumab Compared With Placebo and Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis: AMAGINE-3	Amgen	Spouse's Income for Consulting/Education/Speaking	\$20,000-39,999
Weidner, Melissa	Research Nurse and Co-Investigator	Clinical Trial Protocol CAIN457AUS01 A randomized, double-blind, placebo-controlled, parallelgroup, multicenter study to demonstrate the efficacy of subcutaneous secukinumab [300 mg] as assessed by the Psoriasis Scalp Severity Index (PSSI) at 12 weeks of treatment, compared to placebo, and to assess safety and tolerability up to 24 weeks in adult subjects with moderate to severe scalp psoriasis.	Novartis	Spouse's Income for Consulting/Education/Speaking	\$10,000-19,999
Weidner, Melissa	Research Nurse and Co-Investigator	Vascular Inflammation in Psoriasis Extension (VIP-E) Trial	Abbott Pharmaceutical	Spouse's Income for Consulting/Education/Speaking	\$20,000-39,999
Wright, Cheryl	Associate Professor and Principal Investigator	SketchUp Workshop Program Evaluation	N/A	Intellectual Property	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
Wright, Scott	Associate Professor and Co-Investigator	SketchUp Workshop Program Evaluation	N/A	Intellectual Property	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
Zamrini, Edward	Associate Professor and Principal Investigator	Retrospective analysis of clinical imaging and various testing used in the characterization of dementia	Proactive Memory Services	Equity Interest/Intellectual Property	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
Zamrini, Edward	Associate Professor and Principal Investigator	Memory Care Navigator	Proactive Memory Services	Equity Interest/Intellectual Property	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
Zorn, Meghan	Physician Assisitant and Co-Investigator	PRIDE-HD: A Phase 2, Dose-Finding, Randomized, Parallel-Group, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Pridopidine 45 mg, 67.5 mg, 90 mg, and 112.5 mg Twice-Daily versus Placebo for Symptomatic Treatment in Patients w	Teva	Income for Speaking	\$5,000-9,999